Literature DB >> 2998215

Beneficial effects of cyclosporine compared with azathioprine in cadaveric renal transplantation.

M L Henry, B G Sommer, R M Ferguson.   

Abstract

Recent reports have intimated that the use of antilymphocyte globulin in combination with azathioprine and steroids has ameliorated the beneficial affects of cyclosporine. We believe that even in the absence of significant statistical differences between patient survival rates and graft survival rates of cyclosporine-treated renal transplant patients compared with conventionally treated renal transplant patients, there are distinct advantages to cyclosporine use in renal transplantation. Twenty-three consecutive cadaveric renal transplant patients who received azathioprine, prednisone, and antilymphoblast globulin were compared with 23 cadaveric renal transplant patients who received cyclosporine and prednisone. Fewer statistically significant rejection episodes, multiple rejection episodes, and cytomegalovirus infections were demonstrated in those who received cyclosporine. Most notably, cyclosporine decreased the initial hospital stay, was associated with fewer readmissions, and therefore markedly reduced the initial cost of transplantation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998215     DOI: 10.1016/0002-9610(85)90431-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

Review 1.  The clinical and economic potential of cyclosporin drug interactions.

Authors:  J E Martin; A J Daoud; T J Schroeder; M R First
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

2.  Decreased incidence of infection after renal transplantation with the use of cyclosporine.

Authors:  C d'Ivernois; M Dupon; J F Dartigues; L Potaux; M Aparicio; J Y Lacut
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

3.  A clinical trial of cyclosporine G in cadaveric renal transplantation.

Authors:  M L Henry; E A Elkhammas; E A Davies; R M Ferguson
Journal:  Pediatr Nephrol       Date:  1995       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.